Weighing the Evidence: Clinical Updates on GLP-1 RA and Incretin-Based Therapies

Glucagon-Like Polypeptide-1 Receptor Agonist (GLP-1 RA) and GLP-1 RA/Glucose-dependent Insulinotropic Polypeptide (GIP) therapies have rapidly grown in popularity due to their established roles in the management of type 2 diabetes and obesity. Their demonstrated efficacy has led to expansion into other disease states such as major adverse cardiovascular events (MACE), obstructive sleep apnea (OSA), chronic kidney disease (CKD), and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH).

This webinar will provide a comprehensive overview of currently FDA‑approved GLP‑1 RA and GLP‑1 RA/GIP therapies, including indications, formulations, and real‑world considerations such as insurance and access challenges. We will also explore emerging research, potential future indications, and the next generation of incretin‑based therapies now in development.